{
  "id": "467471f22701f3da",
  "title": "Rilzabrutinib Offers a New , Well - Tolerated Option for Patients With ITP : David Kuter , MD , DPhil",
  "description": "20260105T230000Z",
  "content": "",
  "source": "ajmc.com",
  "source_url": "https://www.ajmc.com/view/rilzabrutinib-offers-a-new-well-tolerated-option-for-patients-with-itp-david-kuter-md-dphil",
  "published_at": "20260105T230000Z",
  "fetched_at": "2026-01-06T00:23:36.488656+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "United States",
  "raw_data": {
    "url": "https://www.ajmc.com/view/rilzabrutinib-offers-a-new-well-tolerated-option-for-patients-with-itp-david-kuter-md-dphil",
    "url_mobile": "",
    "title": "Rilzabrutinib Offers a New , Well - Tolerated Option for Patients With ITP : David Kuter , MD , DPhil",
    "seendate": "20260105T230000Z",
    "socialimage": "https://cdn.sanity.io/images/0vv8moc6/ajmc/a5331bb096348dc55d9f8270415c23d2a13550f9-2879x1612.png",
    "domain": "ajmc.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}